Equities
  • Price (EUR)494.10
  • Today's Change13.60 / 2.83%
  • Shares traded0.00
  • 1 Year change+30.40%
  • Beta--
Data delayed at least 15 minutes, as of Nov 25 2022 16:35 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Elevance Health, Inc., formerly Anthem, Inc., is a health company. It is focused on whole health. It supports health at every life stage, offering health plans and clinical, behavioral, pharmacy and complex-care solutions that promote whole health. It identifies the resources needed to support residents, including the people it serves, and ensure those resources meet local needs. It focuses on advancing health equity, such as ensuring people with disabilities and rural residents can find accessible care. Additionally, it also focuses on prioritizing three areas, such as maternal health, behavioral health, and access to evidence-based medical therapy. It also focuses on providing digitally enabled healthcare. It provides a consumer-centered health system. Carelon is its healthcare services brand and Wellpoint is its health plan brand. Its other brands include Anthem Blue Cross and Blue Shield. Through these brands, it focuses on delivering solutions beyond traditional health insurance.

  • Revenue in USD (TTM)153.25bn
  • Net income in USD6.21bn
  • Incorporated2001
  • Employees98.20k
  • Location
    Elevance Health Inc220 Virginia AvenueINDIANAPOLIS 46204United StatesUSA
  • Phone+1 (317) 488-6000
  • Websitehttps://www.antheminc.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ELV:NYQ since
announced
Transaction
value
BioPlus Specialty Pharmacy Services LLCAnnounced09 Nov 202209 Nov 2022Announced-3.10%--
Data delayed at least 15 minutes, as of Nov 25 2022 18:10 GMT.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.